Novo Nordisk

Obesity Pipeline

News

• 2026-09-21 Capital Markets Day (London, 09:00-15:30 BST, webcast): Executive Management presents a comprehensive overview of strategy, R&D pipeline, business operations and performance - Doustdar's first CMD, one week before EASD Milan
• 2026-09-07 STEP Young phase 3 (children 6 to <12 with obesity, 68 wks): semaglutide + lifestyle met the primary BMI endpoint; 40.4% no longer classified with obesity vs 0% on placebo - first GLP-1 phase 3 readout in this age group (>85% had severe class II/III obesity at baseline)
• 2026-08-27 China's NMPA accepts Novo's marketing application for oral Wegovy (semaglutide 25 mg) for weight management - filed ahead of the early-2027 expiry of semaglutide's regulatory data protection in China, chasing Lilly's end-2025 orforglipron filing
• 2026-08-04 Novo reports Q2 2026 adjusted operating profit of DKK 33.4bn (+11% CER) on adjusted sales of DKK 78.5bn (+7% CER)
• 2026-08-04 Novo raises 2026 outlook to 0% to -6% (CER) for both adjusted sales and operating profit, up from -4% to -12% guided in May, on stronger GLP-1 product sales
• 2026-07-15 European Commission approves the Wegovy pill (oral semaglutide 25 mg), the first oral GLP-1 for weight management in the EU, plus the Wegovy 7.2 mg pen
• 2026-07-01 CMS Medicare GLP-1 Bridge launches: a fixed $50/month copay for Wegovy (injection and pill) and rivals, running through Dec 2027
• 2026-06-08 ADA 2026 readthrough: Novo's CagriSema/zenagamtide data lands incremental; analysts call Lilly the clear winner, widening its obesity lead